contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nanexa-receives-approval-for-late-breaking-abstract-at-ada-congress-in-chicago-in-june

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nanexa är ett drug delivery-bolag med en egenutvecklad plattform som används för formulering av injicerbara depåläkemedel som skapar en tillförsel av läkemedel till blodet. PharmaShell processen baseras på ALD (Atomic Layer Deposition) teknologin som innesluter läkemedelspartiklar med ett tunt skal och skapar möjlighet för läkemedelsbolag att utveckla nya produkter. Nanexa har samarbete med flertalet läkemedelsbolag, huvudsakligen runtom den nordiska marknaden.

Nanexa

Nanexa announces that the results from the recently completed Phase I-study with NEX-22 have been approved as a Late Breaking Abstract at the prestigious ADA Congress (American Diabetes Association...

<div class="mfn-preamble"><p><strong>Nanexa announces that the results from the recently completed Phase I-study with NEX-22 have been approved as a Late Breaking Abstract at the prestigious ADA Congress (American Diabetes Association) held in Chicago June 20-23. </strong></p></div><div class="mfn-body"><p>The abstract presents results from the Phase I-study with NEX-22, developed in collaboration with the renowned CRO Profil in Germany, specializing in diabetes research.<br>NEX-22 is Nanexa´s PharmaShell based one-month depot of the GLP-1 substance liraglutide, intended for the treatment of type 2 diabetes. Liraglutide is currently administrated as a daily injection. NEX-22 is expected to simplify treatment and thereby increase adherence.</p><p>"This is a recognition of our interesting data with NEX-22," says David Westberg, CEO of Nanexa. "We look forward to both scientific discussions and the opportunity to meet companies within the industry. This is a welcome contribution to our business development and strengthens our position in diabetes research and treatment."</p><p>The abstract has been selected to be part of the poster presentation during the congress and will also be published on the journal Diabetes® website in June.</p></div><div class="mfn-footer mfn-contacts mfn-2376405b3437"><p><strong class="mfn-heading-1">For additional information, please contact:</strong></p><hr><p>David Westberg – CEO, Nanexa AB (publ)&nbsp;<br>Phone: +46 70 942 83 03<br>Email:&nbsp;<a rel="noopener" href="mailto:david.westberg@nanexa.se">david.westberg@nanexa.se</a><br><a rel="noopener" href="http://www.nanexa.com/">www.nanexa.com</a></p><p>The company’s Certified Adviser is Carnegie Investment Bank AB (publ).</p></div><div class="mfn-footer mfn-about mfn-c9ba281e2dde"><p><strong class="mfn-heading-1">About Nanexa AB (publ)</strong></p><hr><p>Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.</p><p>Nanexa’s share is listed&nbsp;on Nasdaq First North Growth Market in Stockholm (NANEXA).</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/293f03c0-2df6-41af-806c-bf1fa8596e32/nanexa-receives-approval-for-late-breaking-abstract-at-ada-congress-in-chicago-in-june.pdf" class="mfn-generated mfn-primary">Nanexa Receives Approval for Late Breaking Abstract at ADA Congress in Chicago in June</a></p></div>

Nanexa Receives Approval for Late Breaking Abstract at ADA Congress in Chicago in June